Ford Bio Medical Laboratory INC.

Ford Bio Medical Laboratory INC. was paid $3.92M by Medicaid between Jan 2018 and Dec 2024, across 67 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 48% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Michigan

Rank by total paid#18 of 108

Median peer was paid$588K

This provider vs. median6.7×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	806	$39K
2019	2,491	$77K
2020	16,997	$862K
2021	30,121	$1.12M
2022	30,315	$1.06M
2023	17,302	$498K
2024incomplete	12,652	$263K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	48%	29,276	26,509	$1.90M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	19%	19,312	6,047	$745K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	12%	3,198	2,856	$486K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	8.4%	17,984	16,103	$328K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.1%	4,233	3,608	$81K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.5%	3,152	3,111	$59K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	957	892	$38K
84443	Thyroid stimulating hormone (TSH)	<1%	3,213	3,162	$34K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	449	228	$33K
80053	Comprehensive metabolic panel	<1%	4,191	4,014	$30K
80061	Lipid panel	<1%	3,247	3,192	$28K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	4,581	4,349	$23K

55 more codes

G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	205	$22K
83037		<1%	3,047	$19K
82607		<1%	1,444	$13K
84439		<1%	1,652	$9K
36415	Collection of venous blood by venipuncture	<1%	3,584	$6K
86481		<1%	85	$6K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	133	$6K
84153		<1%	521	$6K
83970		<1%	175	$5K
84481		<1%	305	$3K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	43	$3K
82728		<1%	343	$3K
84480		<1%	325	$3K
82746		<1%	293	$3K
86800		<1%	251	$3K
84403		<1%	142	$2K
83735		<1%	480	$2K
87592		<1%	69	$2K
82670		<1%	99	$2K
84144		<1%	116	$2K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	34	$2K
86803		<1%	185	$2K
86703		<1%	162	$1K
82627		<1%	98	$1K
82533		<1%	131	$1K
83001		<1%	101	$1K
83002		<1%	101	$1K
82248		<1%	420	$1K
83540		<1%	274	$1K
86696		<1%	72	$913.45
87810		<1%	33	$713.24
83003		<1%	55	$560.28
84100		<1%	194	$533.27
86780		<1%	55	$524.47
86695		<1%	60	$517.82
86708		<1%	62	$490.54
81001		<1%	253	$487.27
87481		<1%	15	$406.70
83655		<1%	55	$360.97
86592		<1%	130	$357.52
87086	Culture, bacterial; quantitative colony count, urine	<1%	44	$325.96
84146		<1%	25	$320.75
84402		<1%	13	$253.07
87186		<1%	42	$238.10
83690		<1%	49	$226.88
87088		<1%	42	$222.44
82150		<1%	49	$213.45
82977		<1%	47	$177.06
84550		<1%	69	$138.96
86141		<1%	15	$128.74
87205		<1%	42	$117.14
84436		<1%	101	$110.38
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	391	$11.30
99000		<1%	114	$10.94
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	0%	46	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialABDULHAK, AIDA (OWNER)